NYSE:CTLT - Catalent Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$41.54 -0.28 (-0.67 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$41.82
Today's Range$41.46 - $42.20
52-Week Range$33.42 - $47.87
Volume13.57 million shs
Average Volume950,899 shs
Market Capitalization$5.67 billion
P/E Ratio30.87
Dividend YieldN/A
Beta1.5
Catalent logoCatalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, as well as Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose consisting of ADVASEPT technology; develops biologic cell line, such as GPEx and SMARTag technologies; provides biologics; and offers analytical and bioanalytical development, and testing services. This segment also provides analytical chemical, and cell-based testing and scientific; stability testing; respiratory products formulation and manufacturing; micronization and particle engineering; regulatory consulting; and bioanalytical testing services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:CTLT
CUSIPN/A
Phone732-537-6200

Debt

Debt-to-Equity Ratio2.53
Current Ratio2.18
Quick Ratio1.78

Price-To-Earnings

Trailing P/E Ratio30.87
Forward P/E Ratio26.80
P/E Growth2.07

Sales & Book Value

Annual Sales$2.08 billion
Price / Sales2.67
Cash Flow$2.5345 per share
Price / Cash16.39
Book Value$5.79 per share
Price / Book7.17

Profitability

EPS (Most Recent Fiscal Year)$1.35
Net Income$109.80 million
Net Margins2.62%
Return on Equity21.76%
Return on Assets5.16%

Miscellaneous

Employees10,800
Outstanding Shares133,370,000

Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent (NYSE:CTLT) issued its quarterly earnings data on Tuesday, May, 1st. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.35 by $0.06. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. Catalent had a net margin of 2.62% and a return on equity of 21.76%. Catalent's revenue was up 17.9% compared to the same quarter last year. During the same period last year, the company posted $0.38 earnings per share. View Catalent's Earnings History.

When is Catalent's next earnings date?

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

What price target have analysts set for CTLT?

14 analysts have issued 1 year price targets for Catalent's shares. Their forecasts range from $38.00 to $50.00. On average, they anticipate Catalent's share price to reach $45.8182 in the next twelve months. View Analyst Ratings for Catalent.

Who are some of Catalent's key competitors?

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)
  • Mr. Steven L. Fasman Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)
  • Mr. Barry B. Littlejohns, Pres of Biologics & Specialty Drug Delivery (Age 52)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)

Has Catalent been receiving favorable news coverage?

News articles about CTLT stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 46.66 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.45%), JPMorgan Chase & Co. (3.21%), Champlain Investment Partners LLC (2.72%), American Century Companies Inc. (2.15%), Earnest Partners LLC (1.90%) and Northern Trust Corp (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, BNP Paribas Arbitrage SA, Hood River Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Loomis Sayles & Co. L P and Carillon Tower Advisers Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

Which major investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wells Fargo & Company MN, Prudential Financial Inc., GW&K Investment Management LLC, Impax Asset Management LLC, American Century Companies Inc., Segall Bryant & Hamill LLC and Mackay Shields LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $41.54.

How big of a company is Catalent?

Catalent has a market capitalization of $5.67 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (CTLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.